Abstract
Transcription factor C/EBPα induces normal myeloid differentiation, inactivation of C/EBPα leads to a differentiation block in acute myeloid leukemias (AML), and overexpression of C/EBPα results in AML growth arrest and differentiation. Recent reports suggest that C/EBPα is activated or inactivated via protein–protein interactions. We previously reported that C/EBPα needs to inactivate the proto-oncogene c-Jun via leucine zipper domain interaction in order to induce granulocytic differentiation. We, therefore, hypothesized that c-Jun expression might be elevated in AML and subsequently inactivate C/EBPα. In fact, compared to normal bone marrow mononuclear cells, c-Jun expression is increased in AML patient samples (Affymetrix expression microarray analysis, n=166). c-Jun binds to C/EBPα via the leucine zipper domains and prevents C/EBPα from DNA binding. Inactivation of C/EBPα by c-Jun is necessary for c-Jun to induce proliferation because c-Jun-induced proliferation can be prevented by ectopic overexpression of C/EBPα. The dominant-negative 30-kDa C/EBPα protein, found in AML, fails to downregulate c-Jun mRNA expression in AML patient samples. Thus, our data suggest a model for AML in which c-Jun promotes proliferation and prevents differentiation by inhibiting C/EBPα DNA binding via leucine zipper domain interaction. It might depend on the expression levels of C/EBPα and c-Jun, if inhibition of C/EBPα by c-Jun or if inhibition of c-Jun by C/EBPα is more predominant: proliferation versus differentiation; AML versus normal myeloid development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Behre G, Singh SM, Liu H, Bortolin LT, Christopeit M, Radomska HS, Rangatia J, Hiddemann W, Friedman AD and Tenen DG . (2002). J. Biol. Chem., 277, 26293–26299.
Behre G, Whitmarsh AJ, Coghlan MP, Hoang T, Carpenter CL, Zhang DE, Davis RJ and Tenen DG . (1999). J. Biol. Chem., 274, 4939–4946.
Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS, Nakshatri H and Boswell HS . (1998). Blood, 92, 2450–2460.
Elsaesser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Update.Schoch C, Reddy V, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W and Behre G . (2003). Oncogene, in press.
Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, Larsen RJ, Asou H, Miller CW, Hoelzer D and Koeffler HP . (2002). Blood, 99, 1332–1340.
Iwama A, Osawa M, Hirasawa R, Uchiyama N, Kaneko S, Onodera M, Shibuya K, Shibuya A, Vinson C, Tenen DG and Nakauchi H . (2002). J. Exp. Med., 195, 547–558.
McKnight SL . (2001). Cell, 107, 259–261.
Miller M, Shuman JD, Sebastian T, Dauter Z and Johnson PF . (2003). J. Biol. Chem., 2003 Feb 10 [epub ahead of print].
Mizuki M, Schwaeble J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Boehmer FD, Mueller-Tidow C, Berdel WE and Serve H . (2002). Blood 2002 Dec 5 [epub ahead of print].
Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y and Tenen DG . (2002). Blood, 100, 998–1007.
Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE and Tenen DG . (2001a). Nat. Med., 7, 444–451.
Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W and Tenen DG . (2001b). Nat. Genet., 27, 263–270.
Peer Zada AA, Singh SM, Meisel A, Reddy VA, Elsaesser A, Update.Haferlach T, Tenen DG, Hiddemann W and Behre G . (2003). Oncogene, 22, 2296–2308.
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA and Calabretta B . (2002). Nat. Genet., 30, 48–58.
Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis-Hansen L and Nerlov C . (2001). Cell, 107, 247–258.
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P and Dombret H . (2002). Blood, 100, 2717–2723.
Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT and Tenen DG . (1998). Mol. Cell. Biol., 18, 4301–4314.
Rangatia J, Vangala RK, Treiber N, Zhang P, Radomska H, Tenen DG, Hiddemann W and Behre G . (2002). Mol. Cell. Biol., 22, 8681–8694.
Reddy VA, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK, Tenen DG, Hiddemann W and Behre G . (2002). Blood, 100, 483–490.
Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S, Kern W, Hiddemann W, Eils R and Haferlach T . (2002). Proc. Natl. Acad. Sci. USA, 99, 10008–10013.
Schuster C, Forster K, Dierks H, Elsaesser A, Behre G, Simon N, Danhauser-Riedl S, Hallek M and Warmuth M . (2003). Blood, 101, 655–663.
Schwartz C, Beck K, Mink S, Schmolke M, Budde B, Wenning D and Klempnauer KH . (2003). EMBO J., 22, 882–892.
Shaulian E and Karin M . (2002). Nat. Cell Biol., 4, E131–E136.
Tenen DG . (2003). Nat. Rev. Cancer, 3, 89–101.
Truong BT, Lee YJ, Lodie TA, Park DJ, Perrotti D, Watanabe N, Koeffler HP, Nakajima H, Tenen DG and Kogan SC . (2003). Blood, 101, 1141–1148.
Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W and Behre G . (2003). Blood, 101, 270–277.
Waalwijk Van Doorn-Khosravani SB, Erpelinck C, Meijer J, Van Oosterhoud S, Van Putten WL, Valk PJ, Beverloo HB, Tenen DG, Lowenberg B and Delwel R . (2002). Hematol. J., 3, 324.
Wang H, Goode T, Iakova P, Albrecht JH and Timchenko NA . (2002). EMBO J., 21, 930–941.
Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ and Timchenko NA . (2001). Mol. Cell, 8, 817–828.
Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ and Tenen DG . (1997). Proc. Natl. Acad. Sci. USA, 94, 569–574.
Zhang P, Behre G, Pan J, Iwama A, Wara-Aswapati N, Radomska HS, Auron PE, Tenen DG and Sun Z . (1999). Proc. Natl. Acad. Sci. USA, 96, 8705–8710.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rangatia, J., Vangala, R., Singh, S. et al. Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPα DNA binding via leucine zipper domain interaction. Oncogene 22, 4760–4764 (2003). https://doi.org/10.1038/sj.onc.1206664
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206664
Keywords
This article is cited by
-
Selective antagonism of cJun for cancer therapy
Journal of Experimental & Clinical Cancer Research (2020)
-
JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia
Leukemia (2017)
-
Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution
Nature Genetics (2016)
-
E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation
Cell Death & Disease (2013)
-
Emerging roles of ATF2 and the dynamic AP1 network in cancer
Nature Reviews Cancer (2010)